Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD – Research Report) and Opus Genetics (IRD – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ironwood Pharma (IRWD)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Ironwood Pharma. The company’s shares closed last Wednesday at $3.70.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
Ironwood Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $7.50, implying a 103.3% upside from current levels. In a report issued on February 26, Citizens JMP also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Opus Genetics (IRD)
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Opus Genetics today. The company’s shares closed last Wednesday at $5.11.
According to TipRanks.com, Lowe is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Opus Genetics with a $9.33 average price target, an 86.6% upside from current levels. In a report issued on February 27, Wedbush also maintained a Buy rating on the stock with a $8.00 price target.
